Alpha-Lipoic Acid (ALA)

Phase 3Small molecule

Alpha-Lipoic Acid (ALA) is one of 92 small molecule programs targeting Type 1 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes MellitusActive, not recruiting

Coronary Artery DiseaseNot yet recruiting

Type 1 Diabetes MellitusPreclinical

Active, not recruiting

Coronary Artery DiseasePhase 3

Not yet recruiting

Competition

Competitive Landscape

114 competitors in Coronary Artery Disease

#DrugCompanyPhaseTrials

Xarelto

WWim Janssens

Approved

5 2

Adempas

Lopid

Jardiance

2 5

Pletal

Otsuka

Approved

1 6

Colcrys

Jazz Pharmaceuticals

Phase 3

4 7

Osmitrol

BB. Braun Medical Inc.

Approved

—8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Inomax

Cyklokapron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Not yet recruiting

Coronary Artery Disease

NCT07725484

Clinical

Trials by Indication[1]

Diabetic Polyneuropathy1 trial

Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt

Completed·EEva Pharma·Phase 4·NCT05813496·430 enrolled

Peripheral Neuropathy1 trial

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

Completed·YYuhan Corporation·Phase 4·NCT04846673·151 enrolled

Heart Failure1 trial

Clinical Study of Lipoic Acid on Ischemic Heart Failure

Completed·SShanghai Zhongshan Hospital·Phase 4·NCT03491969·300 enrolled

Type 1 Diabetes Mellitus1 trial

Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

Completed·UUniversity of California, San Francisco·N/A·NCT00187564·40 enrolled

Coronary Artery Disease1 trial

Lipoic Acid in Chronic Ischemic Heart Failure: Assessment of Reduction in Major Adverse Cardiovascular Events

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 3·NCT07725484·1,526 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Alpha-Lipoic Acid (ALA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpha-Lipoic Acid (ALA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpha-Lipoic Acid (ALA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eva Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEva Pharma

Alpha-Lipoic Acid (ALA)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Diabetic Polyneuropathy1 trial

Peripheral Neuropathy1 trial

Heart Failure1 trial

Type 1 Diabetes Mellitus1 trial

Coronary Artery Disease1 trial

References

Drug Info

Quick Facts

Related News